Rick E. Winningham Joins Jazz Pharmaceuticals' Board of Directors
PALO ALTO, Calif., May 5 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that Rick E. Winningham has been appointed to the company's Board of Directors.
Mr. Winningham joined Theravance, Inc. as Chief Executive Officer and a member of the Board of Directors in October 2001, and was appointed Chairman of the Board of Directors in April 2010. From 1997 to 2001 he served as President, Bristol-Myers Squibb (BMS) Oncology/Immunology/Oncology Therapeutics Network (OTN) and also as President of Global Marketing from 2000 to 2001. Over a fifteen-year period with Bristol-Myers Squibb, Mr. Winningham held various U.S. and global management positions.
Mr. Winningham is a member of the External Advisory Board for the College of Business and Administration and Business Hall of Fame at Southern Illinois University and holds a seat on the Advisory Council for the Keck Graduate Institute.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals (Nasdaq: JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information see www.jazzpharmaceuticals.com.
SOURCE Jazz Pharmaceuticals, Inc.
You May Also Like